ProQR (PRQR) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ProQR Therapeutics has appointed Dr. Peter Beal as Chief ADAR Scientist, enhancing their capabilities in RNA editing technology. Dr. Beal, a renowned expert in ADAR biology, will play a pivotal role in optimizing ProQR’s Axiomer RNA editing platform, aimed at developing treatments for genetic diseases. This strategic addition is expected to strengthen ProQR’s position in the cutting-edge field of RNA-based therapies.
For further insights into PRQR stock, check out TipRanks’ Stock Analysis page.